Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 2,401–2,500 of 3,116
Addressing weight loss management in obese gout patients: guidance for future trials
Christensen, R., Haugegaard, T., Morillon, M. B., Gudbergsen, H., Bliddal, H., & Stamp, L. K. (2024) · Exploration of Musculoskeletal Diseases · doi:10.37349/emd.2024.00074 · Cited by 1
Therapeutic Approach to Heart Failure Management: Insight from Clinical Trials
Kumar, A., Fowler, R., Ruggerio, E., Monahan, J., Battle, S. J., Ampadu, J. O., DiPette, D. J., & Potts, J. D. (2026) · Southern Medical Journal · doi:10.14423/smj.0000000000001965
Beyond lifestyle alone: obesity treatment and the future of cardiovascular prevention
Lotto, R. R., & Pickering, M. (2026) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2026.0039
Farmaci innovativi per il trattamento dell’obesità
Masi, D., Tuccinardi, D., & Watanabe, M. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01535-3 · Cited by 1
Jeon, S.-J., Kim, S.-H., Kang, S., Youn, T. J., & Chae, I. (2026) · PLoS ONE · doi:10.1371/journal.pone.0359095
Kardiovaskuläre Pharmakotherapie im Zeitalter RNA-basierter Präzisionsmedizin
Derda, A. A., & Hohneck, A. L. (2026) · Herz · doi:10.1007/s00059-026-05375-9
Liu, Z., Abulaiti, A., Li, D., Li, J., Wahafu, P., Zhang, Y., Maimaitiming, M., Li, S. Y., Li, G., & Yakufu, M. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103221 · Cited by 1
Medical management of obesity: unlocking the potential
Xiang, A. S., & Sumithran, P. (2025) · Climacteric · doi:10.1080/13697137.2025.2455177 · Cited by 1
Jain, D., Mangla, R., Gupta, M., & Chandra, M. (2026) · Archives of Endocrinology and Disorders · doi:10.46889/aed.2026.2208
Pakulska, A. O., Rządzińska, N., Błoch, A. M., Fimiarz, K. J., Kłosowicz, A. K., Miller, M. A., & Kamińska, A. J. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5685
Examining Aging Related Female Adiposity Through the Endocrine Lens
Gülşen, M. R., Pal, L., & Lathief, S. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-24097-2_6
Zidek, W. (2025) · Diabetes aktuell · doi:10.1055/a-2624-1018
“Auch die SELECT-Studie zeigt eine Nephroprotektion bei Patienten mit Übergewicht, aber ohne Diabetes mellitus [5].”
Medical Management of Peripheral Arterial Disease
Ravilla, A. (2026) · Techniques in vascular and interventional radiology · doi:10.1016/j.tvir.2026.101100
Clement, M. A., & Samuel, J. P. (2026) · Pediatric Nephrology · doi:10.1007/s00467-026-07293-8
Semaglutide and survival in lean type 2 diabetes: emerging enigma
Pacheco, A. P. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf116
Qi, H., Gao, Q., Chen, H., Du, X., & Pan, B. (2026) · PeerJ · doi:10.7717/peerj.21713
Goubar, T., Goubar, C., Fenton‐Lee, D., Stefanidis, A., Macdonald, P. S., & Rushworth, R. L. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2026.05.018
Medically Supervised Weight Loss and Effects of Anti-Obesity Medications
Sheer, A. J., Donahoo, W. T., & Johnson-Mann, C. N. (2024) · Springer eBooks · doi:10.1007/978-3-031-72309-4_14
Raslan, M. A., Nabi, H. A., Dreher, L. A., Osta, S. A., Serra, V. D. S. B., Ayoub, C., Masry, H. E., & Shamoun, F. E. (2026) · Diagnostics · doi:10.3390/diagnostics16111742
“These findings may have important clinical implications for patients with TAA, particularly those with coexisting metabolic disease, where GLP-1 RAs are already commonly prescribed [10–14].”
InfluentialCardiovascular and Kidney Effects of Glucagon-Like Peptide 1 Receptor Agonists
Sattar, N. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00013-6
Abedi, M. M., Alabid, I., Alghoul, W. I. I., Salama, R. A. A., Lami, K. A. H. A., Marzougui, H., Swalha, B. R. R., Shaikh, S. A., Khan, S. S., & Mohamed, N. A. E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103767
Cardiovascular-Kidney-Metabolic Syndrome: Rethinking Risk, Redefining Care
Lan, N. S. R., Psaltis, P. J., Alicic, R. Z., & Arnott, C. G. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.09.001
Potential Benefits of Remission of High Childhood BMI Keep Increasing
Bjerregaard, L. G. (2025) · Diabetes Care · doi:10.2337/dci25-0084 · Cited by 1
江崎, 治. (2011) · Medical Entomology and Zoology
Hypertension at an Inflection Point
Agarwal, R. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.05.005 · Cited by 1
Faust, J. S. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.035
Proposal for a Value-Based Agreement to Reimburse Anti-obesity Medicines in Traditional MedicarePreprint
Ward, A. S., Trish, E. E., Goldman, D. P., & Lakdawalla, D. (2025) · medRxiv · doi:10.1101/2025.07.10.25331289 · Cited by 1
Lǐ, Y., Lv, C., Cao, L., Sun, L., & Ma, Y. (2026) · Biomedical Reports · doi:10.3892/br.2026.2165
“The pooled effect size, indicating a 32% reduction in MACE, aligns with findings from the SELECT trial, where semaglutide reduced cardiovascular events by 20% in patients with obesity but without diabetes (11).”
InfluentialHu, X., Xiao, J., Wang, Z., Huang, X., Zhao, H., & Yang, C. (2026) · medRxiv · doi:10.64898/2026.06.15.26355649
Velasco, A., Ramos, I. P., Alonso, P. R., Sanz, C. D., Tello, R., & Solís, J. (2026) · Revista Clínica Española · doi:10.1016/j.rce.2025.502455
Tian, Z., Sternberg, M., Willerding, J. M., Schmidt-Ott, K. M., Melk, A., & Schmidt, B. (2026) · medRxiv · doi:10.64898/2026.01.28.26345070
Prise en charge pharmacologique de l’obésité : l’apport des nouvelles classes médicamenteuses
Bauduceau, B., Bordier, L., Schlienger, J.-L., & Monnier, L. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.11.008 · Cited by 3
Tirzepatide and Cardioprotection in Type 2 Diabetes: Insights From SURPASS ‐ CVOT
Cosentino, N., Krittanawong, C., & Pontone, G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70766 · Cited by 1
“…Obesity (SELECT) and albiglutide and cardiovascular outcomes in patients with Type 2 diabetes and cardiovascular disease (HARMONY OUTCOMES) trials [8, 9] indicates that the cardiovascular benefits of incretin-based therapies may occur independently of glucose lowering and with only modest weight…”
Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly
Bianchettin, R. G., Poirier, P., López-Jiménez, F. A., Lavie, C. J., & Piché, M. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00777-2 · Cited by 1
Angioedema After Accidental Semaglutide Dosing Error: A Case Report
Kraft, B. D., & Matuszak, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103705 · Cited by 1
“The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has increased exponentially over recent years as accumulating data support broad benefits outside of glycemic control, including reducing cardiovascular disease [1,2], kidney disease [3,4], and obesity [5].”
InfluentialRaveendra, K., Joseph, T., Kang, J., Hurdus, B., Cutting, U., Haris, M., Younsi, T., Aslam, A., Petrie, M. C., Metra, M., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag091
Of Fasts and Feasts: Catholic Ethics and the Right Use of GLP-1 Agonists for Weight Loss
Starr, A. Y. A. (2026) · The Linacre Quarterly · doi:10.1177/00243639261450700
GLP-1 Receptor Agonists beyond Glycemic Control: Physiology and Pharmacological Evidence
Amate, P. (2026) · Open Journal of Pharmacology and Pharmacotherapeutics · doi:10.17352/ojpp.000029
Long-term effects of weight-reducing drugs in people with hypertension
Spary-Kainz, U., Posch, N. A. S., Radl-Karimi, C., Jeitler, K., Krenn, C., Siebenhofer, A., Berghold, A., Horvath, K., Winterholer, S., & Semlitsch, T. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub6 · Cited by 1
Nagapetyan, A. R., Pavlova, T. I., & Li, J. (2024) · Russian Journal of Economics · doi:10.32609/j.ruje.10.125107
McCartney, F. (2024) · Therapeutic Delivery · doi:10.1080/20415990.2024.2365621
Real‐World vs. Randomized Trial Evidence for Incretin‐Based Therapies: A Narrative Review
Bloomgarden, Z. T. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70248 · Cited by 1
Reddy, Y. N. V., & Bergeron, N. P. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.06.010
Bianchini, L., Martins, G. A. R., & Myatra, S. N. (2026) · Critical Care Science · doi:10.62675/2965-2774.20260166
Semaglutide for Organ Protection
Kharb, S., Bhattacharjee, B., Karuppan, A., V, Khaire, S. S., Routray, P., Ganta, S., Pakhale, K., Pareek, R., Matta, R., Sabharwal, M., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_27_26
Review of Efficacy and Safety of Semaglutide in the Management of Obesity
Han, S., & Park, T. E. (2024) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2024.34.1.1
Liu, J., Chen, Z., Yang, Q., Lin, H., Wang, S., Li, M., Wang, T., Zhao, Z., Xu, M., Chen, Y., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01379-y · Cited by 2
Rajan, K., Jutley, A., Holliday, M. W., & Navaneethan, S. D. (2026) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s522424
Kunicki, M., Katulska, Z., Wolert, W., & Kunicka, A. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109025
Kotlyarov, S. N., & Котлярова, А. А. (2026) · Pharmacoepidemiology · doi:10.3390/pharma5030025
“…(the original drug Ozempic (Novo Nordisk, Bagsværd Denmark)) was registered in Russia only for type 2 diabetes and cardiovascular risk reduction but not for obesity, although its effectiveness in reducing body weight has been established by large randomized controlled trials (RCTs) [15,19,35].”
InfluentialInflammation in atherosclerosis: Drivers, mechanisms and therapies
Su, Z., & Xu, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.047 · Cited by 1
Malmborg, M. W., El-Chouli, M. H., Andersen, C. F., Elmegaard, M., Garred, C. H., Zahir, D., Butt, J. H., Christensen, D. M., Nouhravesh, N., Fosbøl, E. L., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03062-3
Current trends in semaglutide therapy and strategies to improve its bioavailability
Nayak, S., Dessai, A. D., & Nayak, U. Y. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2688990 · Cited by 3
“…targeted benefits: the SELECT trial demonstrated a significant reduction in major cardiovascular events in patients with over-weight or obesity without diabetes [105], while the FLOW trial established its efficacy in improving renal outcomes for patients with T2DM and chronic kidney disease [106].”
Sun, D., Wang, X., Wang, H., Shen, Z., Meng, X., & Zhou, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933732
“In addition to improving glycemic control and body weight, randomized evidence supports cardiovascular, kidney-protective, weight-management, and selected obesity-related HFpEF bene fi ts in the populations studied (23, 36, 44 – 46, 50, 51, 87 – 95).”
Severe Infections as a Novel Risk‐Enhancing Factor for Incident Heart Failure
Demmer, R. T., Grossardt, B. R., Khan, S. S., & Borlaug, B. A. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047537
Avances farmacológicos en la lucha contra la obesidad
Portero, P. C. (2025) · Panorama actual del medicamento · doi:10.63105/49.481.1
Strategies to Overcome Metabolic Syndrome and Related Diseases
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-5556-9
Revolución metabólica: redefiniendo la endocrinología con nuevas terapias basadas en incretinas
Hernández, A. R., Araujo, J. E. G., Castillo, J. F. D., Martínez, M. E. A., Cohen, N. E. Z., Navarro, A. F. U., Chavez, M. A. N., & Morales, A. L. L. (2025) · Star of Sciences Multidisciplinary Journal · doi:10.63969/tg610p62
Hypertensive Disorders of Pregnancy and Cardiovascular-Kidney-Metabolic Syndrome
Ezzat, D., Pabón, M. A., Li, L., Chang, A., Moor, N. D., Yu, Z., Cho, S. M. J., Natarajan, P., Spracklen, C. N., LeBlanc, E. S., et al. (2026) · Hypertension · doi:10.1161/hypertensionaha.126.27750
Canecki-Varžić, S., Bilić-Čurčić, I., Bakula, M., Bulum, T., Naglić, M. Č., Delić-Brkljačić, D., Wensveen, T. T., Vitković, D. F., Jurišić‐Eržen, D., Klobučar, S., et al. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1834323 · Cited by 1
“Semaglutide also showed diabetes prevention signals in SELECT (Packer et al., 2025).”
InfluentialMetabolic and bariatric surgery in an era of anti-obesity medication
Lübbe, J. (2025) · South African journal of gastroenterology and hepatology. · doi:10.36303/sajgh.2963
Mazzone, P. M., Giacoppo, D., Ammirabile, N., Mauro, M. S., Spagna, F., & Capodanno, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag430
Next-generation anti-obesity drugs: Mechanisms, molecules, and momentum
Mukheja, Y., Kondepudi, K. K., Chopra, K., & Bishnoi, M. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100701 · Cited by 1
Sattar, N. A. (2025) · Obesity · doi:10.1002/oby.70017
The Cardioprotective Effects of Semaglutide in Obese Patients: Literature Review
Pinheiro, E. G. H., de Oliveira, G. F., Moreira, J. P. B., Oliveira, A. S. F., de Figueiredo, A. G., de Carvalho, R. G., Rodrigues, F. S. M., & Fernandes, H. J. (2024) · Journal of Medical Residency Review · doi:10.37497/jmrreview.v3i00.59
Mansouri, E. S., de Queiroga, F. F., Barbosa, L., Azevedo, A. K., Donaldy, W., Mirbolouk, M. J., Freire, C. V. S., Rivera, A., Félix, I. F., Abreu, M., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.044249 · Cited by 1
Diab, A. R., Chang, T. H. W., Diab, O., & Kheir, M. M. (2026) · Hip International · doi:10.1177/11207000261476202
Implementing the 2025 AACE Obesity Algorithm: Bridging Guidelines With Real-World Clinical Practice
Sloan, L. A., Blanchette, J., & Patham, B. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.02.017
Postmenopause und Gewicht: Wechselseitige Einflüsse und die Rolle der Hormonersatztherapie
Bachmann, A. (2026) · Die Gynäkologie · doi:10.1007/s00129-025-05459-3
What REDEFINE 5 signals for obesity trials in Asia and beyond
Kang, Y. M., & Aroda, V. R. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00012-4
What and how you eat can increase the effects of GLP-1 without drugs
Scourboutakos, M. J. (2025) · The Conversation · doi:10.64628/aam.3qkq674hj
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception
Koca, N., Uyar, S., Şahintürk, Y., Yıldız, H., Prato, S. D., & DeFronzo, R. A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03346-2
“…proven benefit; a pre-specified indirect comparison against an imputed placebo showed a lower rate of major adverse cardiovascular events the STEP and SELECT programs revealed substantial effects on hepatic steatosis, fibrosis, and cardiovascular outcomes, even in non-diabetic individuals [10–12].”
Gurgoglione, F. L., & Niccoli, G. (2024) · European Cardiology Review · doi:10.15420/ecr.2024.43
Ozempic: the gold standard for weight normalisation or a “lifeboat”
Salivon, H., & Klymenko, O. (2026) · Ukrainian Scientific Medical Youth Journal · doi:10.32345/usmyj.1(160).2026.45-49
Costa, T. A., Vest, A. R., & Harrington, J. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001284
Liu, C., Hui, Q., Linchangco, G. V., Dabbs‐Brown, A., Zhou, J. J., Joseph, J., Reaven, P. D., Rhee, M. K., Djoussé, L., Cho, K., et al. (2026) · medRxiv · doi:10.64898/2026.04.10.26350615
SOP – Einsatz von GLP-1-Analoga in der hausärztlichen Praxis
Kirner, A. (2026) · Allgemeinmedizin up2date · doi:10.1055/a-2748-9009
Medikamentöse Adipositastherapie bei Typ-2-Diabetes
Kantowski, T., Wiesch, C. S. Z., Aberle, J., & Lautenbach, A. (2024) · CME · doi:10.1007/s11298-024-3862-3
Hägg, D. A., Li, L., Beeve, A. T., Scheller, E. L., Bellman, J., Anesten, F., Zlatkovic, J., Gasull, A. D., Font‐Gironès, F., Movérare‐Skrtic, S., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-40431-8
Echocardiographic evaluation and clinical implications of cardiac remodeling in obesity
Okushi, Y., Takahashi, T., & Kusunose, K. (2026) · Journal of Echocardiography · doi:10.1007/s12574-026-00721-6
“GLP-1 RAs have gained considerable attention due to their potent weight-reducing effects and reported cardiovascular benefits in obesity without diabetes [117 , 118].”
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1
“In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease without diabetes, providing direct evidence of cardiovascular benefit beyond weight reduction [224].”
InfluentialMechanism-driven therapy for diabetic cardiovascular disease
Sanchis‐Gomar, F., Lavie, C. J., Carbone, S., & Neeland, I. J. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.84
Wong, J. A., Conen, D., Doumouras, A., van Reekum, E. V., Bangdiwala, S., Balasubramanian, K., Bashir, S., Rangarajan, S., Piché, M., Pettigrew, M., et al. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107544
Zhou, X., Jeong, S., Chen, Q., Targher, G., Byrne, C. D., Chew, N. W., Younossi, Z. M., Lip, G. Y. H., Tilg, H., George, J., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01255-z · Cited by 3
Sigalov, A., & Frishman, W. H. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001468
Interruption of Early Cardiovascular Risk Pathways With GLP-1-Based Therapy for Obesity
Everett, B. M., & Ostrominski, J. W. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.05.011
Vikash, F., Valencia, S. O., Yang, Q., Rubin, S., & Garg, S. (2026) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000001037 · Cited by 1
“For normal or overweight patients receiving GLP-1RA therapy, clinicians should anticipate a higher risk of IBP and consider enhanced preparation strategies, including intensi fi ed bowel regimens or extended dietary restriction, as recommended in existing guidelines (3,5,27).”
Santiago, F. B., Meseguer-Hernández, A., Cayuelas, J. M. A., Guirao-Balsalobre, M. D. C., Mármol-Lozano, M. D. R., & Castillo, J. A. (2024) · REC CardioClinics · doi:10.1016/j.rccl.2024.07.001 · Cited by 2
Kraft, L., Latus, J., & Schanz, M. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00844-4
Targeting Obesity: The Role of GLP-1 Receptor Agonists in Achieving Sustainable Weight Loss
Vamplew, B. (2025) · Lynchburg Journal of Medical Science · doi:10.63932/3067-7106.1031 · Cited by 1
Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide
Kozato, A., Patel, S. S., Orandi, B. J., Massie, A. M., Mańkowski, M., Fielding, C. R., Segev, D. L., Parikh, M., & Chhabra, K. R. (2026) · Surgical Endoscopy · doi:10.1007/s00464-026-13147-z · Cited by 1
Tucker, S. L., & Humadi, S. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08741-y
“In addition, sema-glutide demonstrates cardiovascular risk reduction independent of weight effects, as shown in the SELECT trial [ 31].”
Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity
Mollero, E. L. M., Dozzani, I., Biamonte, E., Bendotti, G., Marzullo, P., Aimaretti, G., & Gallo, M. (2026) · Nutrients · doi:10.3390/nu18162654 · Cited by 3
Wang, E. Y., Xu, K., Shao, Y., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1904928
“Recent discovery of sodium-glucose cotransporter 2 inhibitors (10, 11) and glucagon-like peptide-1 (GLP1) agonists (12, 13) for cardiovascular benefits in diabetes patients fuels clinical endeavor of exploring these diabetes drugs for further cardiovascular benefits in non-diabetic patients.”
Vafeidou, K., Koufakis, T., Stavropoulos, K., Zarfeiadou, M., Doumas, M. N., & Patoulias, D. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2634086
“Additionally, the incidence of serious adverse events in the SELECT trial was lower in the semaglutide arm compared with the placebo arm, indicating an overall favorable safety-efficacy profile in a high-risk population [10].”
Compound J27 alleviates obesity-induced cardiomyopathy by targeting JNK2
Dong, H., Wang, A., Ye, J., Qiao, L., Xia, Y., Cui, Y., Lin, M., Xiong, Y., Jin, L., Yang, Y., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117278
Stiefelhagen, P. (2026) · Info Diabetologie · doi:10.1007/s15034-025-5217-x
Ahmad, W. A., Sagy, Y. W., Arbel, R., Battat, E., Diker, D., Lavie, G., & Reges, O. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107164 · Cited by 1
Levi, J., Cross, S., Ramesh, N., Venter, F., & Hill, A. M. (2026) · Obesity · doi:10.1002/oby.70241 · Cited by 8
Petrie, M. C., Januzzi, J. L., Harrington, J., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.05.041
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
